Le Lézard
Classified in: Health, Science and technology
Subject: ANNUAL MEETINGS

Cannabix Technologies Annual General Meeting Results


VANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company") announces the results of its annual general meeting of common shareholders held on July 28, 2023 in Burnaby. Resolutions passed at the meeting included the appointment of Saturna Group Chartered Accountants LLP as auditors for the ensuing year and the re-election of Rav Mlait, Dr. Raj Attariwala, Bryan Loree, Kal Malhi, and Thomas Clarke as directors.

We seek Safe Harbor.
On behalf of the Board of Directors

"Rav Mlait"

CEO
Cannabix Technologies Inc.

For further information, contact the Company at [email protected]

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.



These press releases may also interest you

at 18:05
Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 13:27
Industrial Automation Market In Life Sciences Industry size is set to grow by USD 5.06 bn from 2024-2028, growing global demand for healthcare services to boost the market growth, Technavio
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 10:15
Ibbaka Revenue Retention Maturity Model Helps B2B SaaS Companies Uncover Hidden Opportunities Within Customer Revenue Growth
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

at 08:35
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 06:47
After Launching Massive Camp Giveaway for NYC Families Affected by "Summer Rising" Crisis, Brains & Motion Education (BAM!) Extends Initiative to SF Bay Area Families
After tens of thousands of NYC children were turned away from "Summer Rising," New York City's popular, free summer enrichment program, Brains & Motion launched a campaign offering camps at NYU for a small fraction of the up-to-$1400 per week price...

More news about Science and technology...


News published on and distributed by: